Sunitinib combined with pemetrexed and cisplatin: results of a phase I dose-escalation and pharmacokinetic study in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer and mesothelioma

[1]  L. Seymour,et al.  Brief Report: A Phase II Study of Sunitinib in Malignant Pleural Mesothelioma. The NCIC Clinical Trials Group , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[2]  L. Tye,et al.  A phase I dose-escalation and pharmacokinetic study of sunitinib in combination with pemetrexed in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer , 2011, Cancer Chemotherapy and Pharmacology.

[3]  W. Franklin,et al.  Anaplastic Lymphoma Kinase Gene Rearrangements in Non-small Cell Lung Cancer are Associated with Prolonged Progression-Free Survival on Pemetrexed , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[4]  J. Burke,et al.  Randomized phase II multicenter study of the efficacy and safety of sunitinib on the 4/2 versus continuous dosing schedule as first-line therapy of metastatic renal cell carcinoma: Renal EFFECT Trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Y. Bang,et al.  Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. , 2011, The New England journal of medicine.

[6]  P. Stephenson,et al.  Sunitinib in combination with gemcitabine plus cisplatin for advanced non-small cell lung cancer: a phase I dose-escalation study. , 2010, Lung cancer.

[7]  S. Jiao,et al.  Pemetrexed plus cisplatin/carboplatin in previously treated locally advanced or metastatic non-small cell lung cancer patients , 2010, Journal of experimental & clinical cancer research : CR.

[8]  G. Scagliotti,et al.  Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  M. Socinski,et al.  Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer , 2009, British Journal of Cancer.

[10]  U. Harmenberg,et al.  Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  J. Blay,et al.  Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. , 2009, European journal of cancer.

[12]  R. Sainson,et al.  Angiogenesis: an integrative approach from science to medicine , 2008 .

[13]  Johan Vansteenkiste,et al.  Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  H. Rugo,et al.  Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  M. Socinski,et al.  Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  C. Heldin,et al.  Identification of a subset of pericytes that respond to combination therapy targeting PDGF and VEGF signaling , 2007, International journal of cancer.

[17]  R. Motzer,et al.  Sunitinib efficacy against advanced renal cell carcinoma. , 2007, The Journal of urology.

[18]  L. Chow,et al.  Sunitinib: from rational design to clinical efficacy. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  Jung Hun Song,et al.  An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases. , 2006, The Journal of clinical endocrinology and metabolism.

[20]  Y. Maehara,et al.  Platelet-derived growth factor-AA is an essential and autocrine regulator of vascular endothelial growth factor expression in non-small cell lung carcinomas. , 2005, Cancer research.

[21]  M. Byrne,et al.  Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[22]  Claude Denham,et al.  Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  D. Kwiatkowski.  Rhebbing up mTOR: New Insights on TSC1 and TSC2, and the Pathogenesis of Tuberous Sclerosis , 2003, Cancer biology & therapy.

[24]  N. Pryer,et al.  SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. , 2003, Molecular cancer therapeutics.

[25]  M. Heinrich,et al.  SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. , 2003, Blood.

[26]  A. Yuan,et al.  Vascular endothelial growth factor 189 mRNA isoform expression specifically correlates with tumor angiogenesis, patient survival, and postoperative relapse in non-small-cell lung cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[28]  K. O'Byrne,et al.  Platelet-derived endothelial cell growth factor expression correlates with tumour angiogenesis and prognosis in non-small-cell lung cancer. , 1997, British Journal of Cancer.

[29]  N. Pryer,et al.  SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model , 2004, Clinical & Experimental Metastasis.

[30]  Juthamas Sukbuntherng,et al.  In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[31]  M Van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.